Researchers from La Jolla Institute for Immunology (LJI), Scripps Research, and IAVI have reported a major advance in HIV vaccine development, demonstrating an experimental vaccine strategy that produced unusually strong…
As reported on PharmaBiz, Merck has announced a new agreement with the ADAP Crisis Task Force (ACTF) aimed at improving access to its recently approved HIV treatment, Idvynso (doravirine/islatravir), for…
As reported on Business Wire, Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application for a 300‑mg oral formulation of…
Merck and Gilead Sciences reported contrasting late-stage outcomes on Monday, pairing a promising advance in HIV treatment with the discontinuation of a high-profile lung cancer trial after underwhelming survival results.…
The US Food and Drug Administration (FDA) has approved Idvynso, a groundbreaking two-drug single-tablet regimen combining 100 mg doravirine and 0.25 mg islatravir, for treating HIV-1 infection in adults. As…
As reported on Healthline, a man in Norway has entered sustained HIV remission following a stem cell transplant, becoming one of a small number of individuals worldwide to achieve what…
The traditional model of HIV care has long centered on one fundamental requirement: patients must take medication every single day, without fail. Yet this model increasingly conflicts with the complex…
As reported on FierceBioTech, Gilead Sciences has closed one of its midstage clinical studies evaluating an experimental HIV regimen, following ongoing safety concerns that prompted U.S. regulators to intervene last…
Researchers have created a fundamentally new class of HIV-fighting molecules by combining two separate antiviral mechanisms into a single engineered protein. Early laboratory results, reported by Forbes, suggest this integrated…
As reported on Forbes, a class of drugs first introduced to combat HIV is now demonstrating unexpected promise for patients with rare genetic and mitochondrial disorders. Once designed to block…
Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial on December 15, 2025 and reported by Drugs.com, marking a significant advancement in HIV treatment options. The trial…
My name is Jessica Glaspie, and I have been living with HIV for over 15 years! A lot of people think that life and love with HIV is almost impossible…
By Thresa Giles, CEO — Hope & Help Center of Central Florida Since HIV was first identified in 1983, there has been a growing, persistent stigma surrounding it. People have…
In a significant advancement for HIV prevention, the Centers for Disease Control and Prevention (CDC) has issued a strong recommendation for Yeztugo (lenacapavir), Gilead Sciences’ long-acting, twice-yearly pre-exposure prophylaxis (PrEP)…
South Africa is on the brink of a major shift in HIV prevention, with plans to introduce lenacapavir—a twice-yearly injectable—at select public clinics by April 2026. As reported by All…
The landscape of HIV treatment continues to evolve, and a significant milestone has just been reached with the FDA’s approval of Rukobia (fostemsavir), a novel therapy from ViiV Healthcare. Reported…
According to a story from Forbes, Joe Rogan's hit podcast "The Joe Rogan Experience," which is the most popular podcast on Spotify and commands an enormous following, has been no…
Globally, an estimated 39.9 million people live with human immunodeficiency virus (HIV). HIV is an infection which, over time, damages the immune system. This condition can be spread through sexual…
Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…
Today, American Gene Technologies (AGT) announced that they will soon be beginning a Phase 1 clinical trial for AGT103-T, a potential treatment for HIV. The unique gene therapy, developed…
COVID-19 diagnoses are growing at a rapid rate, to the point where data is changing daily. As of today, there are 4.23 million diagnosed cases worldwide, with 1.39 million in…
According to Bronchiectasis News, patients with both HIV and bronchiectasis often have a difficult time being diagnosed with the respiratory condition. After researchers examined data from 14 patients, they discovered…
In the wake of Martin Luther King Jr. Day, those with rare diseases have vocalized some of the dreams that they have for the healthcare industry. With all of the…
As reported in RadioFreeEurope, Russian biologist Denis Rebrikov is currently challenging the norm of caution regarding gene-editing in the science world, with efforts to gain the go-ahead from Russia to…
According to the publication from RedlionTrader, a second man infected with HIV seems to have been cleared of the infection, those scientists remain highly cautious of touting the case as…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
